Praxis Precision Medicines, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026New collaboration broadens how ulixacaltamide can be delivered to patients and strengthens its market position.
Changing accountants is routine but investors should know who verifies the company's financial statements.
Drug approval decision delayed to December 27, 2026, giving the FDA more time to evaluate the medicine.
Fast-track status for seizure treatment means quicker development path and potential approval earlier.
Board members and management compensation reflect who controls the company and runs it daily.
Failed trial outcome requires strategy reassessment and raises questions about this drug's future.
Quarterly financial results show how much money the company earned or spent during the period.
Stocky reads Praxis Precision Medicines, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Praxis Precision Medicines, Inc.'s most recent tracked filing was a 8-K on 7 Jul 2026: Partners with Remagine Labs to develop transdermal patch.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.